newsfilter
← Latest News
GlobeNewswire·

Sigilon Therapeutics Reports First Quarter 2022 Financial Results And Business Highlights

On track to announce results from preclinical studies of SIG-005 in second half of 2022 Current cash position expected to fund operating plans into 2024 CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX),